Defining Best Practices for Biosimilar Development


The global market for biosimilar drugs totaled more than $3 billion in 2016 and is expected to skyrocket to more than $10 billion by 2021, according to market research data. BioAgilytix’s Arno Kromminga, Ph.D. sat down with AAPS Newsmagazine discuss how the AAPS Ligand-Binding Assay Bioanalytical (LBABFG) and Biosimilars focus groups created the Biosimilars Action Program Committee (APC) to identify the bioanalytical challenges unique to biosimilar development and recommend practices to address these challenges.

Click for full article

Share This